FES Antikörper (truncated)

Produktnummer ABIN2464051

Dieses Maus Monoklonal-Antikörper erkennt spezifisch FES in WB, ELISA und IHC. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für FES Antikörper (truncated) (ABIN2464051)

Target: FES (Feline Sarcoma Oncogene (FES))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser FES Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Klon: 2E3G3-2G9G1

Produktdetails anti-FES Antikörper

Bindungsspezifität: truncated

Immunogen: Ni-NTA purified truncated recombinant FES-His expressed in E. Coli strain BL21 (DE3).

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Western Blot:1:500 - 1:2,000
IHC(P):1:500 - 1:2,000
ELISA:Propose dilution 1:10,000.
Determining optimal working dilutions by titration test.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Lagerung: -20 °C

Informationen zur Lagerung: FES monoclonal antibody can be stored at -20 °C, stable for one year.

Details zu FES

Target: FES (Feline Sarcoma Oncogene (FES))

Andere Bezeichnung: FES

Hintergrund: FES (feline sarcoma oncogene) and Fer are the only two members of a unique family of cytoplasmic protein tyrosine kinases. FES and Fer contain a central Src homology-2 (SH2) domain and a carboxy-terminal tyrosine kinase catalytic domain. They are structurally distinguished from other members of cytoplasmic protein tyrosine kinase subfamilies by the presence of amino-terminal Fer/CIP4 homology and coiled-coil domains. FES was originally identified as an oncogene from avian and feline retroviruses. Human c-Fes has been implicated in myeloid, vascular endothelial and neuronal cell differentiation. FES has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Mutations may activate the FES kinase and thereby contribute to cancer. However, recent data strongly suggests that the c-FES protein-tyrosine kinase is a tumor suppressor rather than a dominant oncogene in colorectal cancer.

Gen-ID: 2242

UniProt: P07332

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Signaling Events mediated by VEGFR1 and VEGFR2